Viral vector platforms within the gene therapy landscape.

Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. · 2021

Read Viral vector platforms within the gene therapy landscape. by Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7868676.txt.

Introduction

Bulcha and co-authors survey viral carrier platforms across the gene therapy field. The field spans a 40-year history of swings. Big wins for patients mix with harsh setbacks. Some trial patients suffered grave harm or died. Viral carriers sit at the heart of both.

These carriers ferry gene fixes into cells. The last 5 years brought a wave of approvals. Designs treat cancer and single-gene diseases alike. Three platforms lead the field. They rest on adenoviruses, adeno-associated viruses, and lentiviruses. The authors explain how each one works. Their roles in past wins are set out. Limits that still cap the field get frank review.

Catalog record

CREATORBulcha JT, Wang Y, Ma H, Tai PWL, Gao G.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE168 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7868676

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Viral vector platforms within the gene therapy landscape By Jote T. Bulcha, Yi Wang, Hong Ma, Phillip W. L. Tai, Guangping Gao Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-021-00487-6 ABSTRACT Throughout its 40-year history, the field of gene therapy has been marked by many transitions. It has seen great strides in combating human disease, has given hope to patients and families with limited treatment options, but has also been subject to many setbacks. Treatment of patients with this class of investigational drugs has resulted in severe adverse effects and, even in rare cases, death. At the heart of this dichotomous field are the viral-based vectors, the delivery vehicles that have allowed researchers and clinicians to develop powerful drug platforms, and have radically changed the face of medicine. Within the past 5 years, the gene therapy field has seen a wave of drugs based on viral vectors that have gained regulatory approval that come in a variety of designs and purposes. These modalities range from vector-based cancer therapies, to treating monogenic diseases with life-altering outcomes. At present, the three key vector strategies are based on adenoviruses, adeno-associated viruses, and lentiviruses. They have led the way in preclinical and clinical successes in the past two decades. However, despite these successes, many challenges still limit these approaches from attaining their full potential. To review the viral vector-based gene therapy landscape, we focus on these three highly regarded vector platforms and describe mechanisms of action and their roles in treating human disease. INTRODUCTION Gene therapy is the treatment of a genetic disease by the introduction of specific cell function-altering genetic material into a patient. The key step in gene therapy is efficient gene delivery to the target tissue/cells, which is carried out by gene delivery vehicles called vectors. There are two types of vectors: viral and non-viral. Non-viral vectors will not be discussed in this review. Contemporary viral vector-based gene therapy is achieved by in vivo delivery of the therapeutic gene into the patient by vectors based on retroviruses, adenoviruses (Ads) or adeno-associated viruses (AAVs) (Fig. 1). Alternatively, a therapeutic transgene can be delivered ex vivo, whereby cells of a patient are extracted and cultured outside of the body. Cells are then genetically modified by introduction of a therapeutic transgene and are then re-introduced back into the patient. There are four basic gene therapy approaches as follows: gene replacement, the delivery of a functional gene to replace a non-working gene; gene silencing, inactivation of a mutated gene that has become toxic to cells; gene addition, over expression of a “foreign” or exogenous gene to impact cellular function; and gene editing, a permanent manipulation of a gene in a patient’s genome.Fig. 1Summary of viral gene therapy modalities.In vivo gene therapy entails the direct administration of vector carrying a therapeutic transgene into the patient. Ex vivo gene therapy involves the extraction of a patient’s cells or from an allogenic source, genetic modification by a vector carrying a therapeutic transgene, selection and expansion in culture, and infusion to re-introduce the engineered cells back into the patient The first gene therapy trial, at least conceptually, was performed by Dr. Stanfield Rogers, who treated two sisters who had hyperargininemia.1 The treatment was based on his observations that patients with Shope papilloma virus had decreased serum arginine levels. Unfortunately, the trial failed to reverse the disease, as the Shope papilloma genome did not encode for arginase production. In a 1980 study that was not formally published, Dr. Martin Cline attempted to insert recombinant β-globin, a factor needed in the production of hemoglobin, into bone marrow cells of two patients with β-thalassemia.2 The transfected cells were then re-introduced back into the patients. Although groundbreaking at the time, this first attempt at an ex vivo gene therapy was ultimately a failure. Nonetheless, these two efforts were among several others that endeavored to deliver genetic material to patients, in the hopes of treating disease. It was not until the early 90s that viral vector gene therapies found clinical success. A trial led by French Anderson, Michael Blaese, and Steven Rosenburg also employed an ex vivo strategy in treating a patient named Ashanthi DeSilva, who had adenosine deaminase deficiency severe combined immunodeficiency disease (ADA-SCID). Several infusions of T cells transformed by a recombinant retrovirus carrying the ADA gene were administered, resulting in what is regarded as the first successful gene therapy in humans.3,4 The use of viruses for therapy has long been practiced and actually belongs to a class of viral-based treatments known as virotherapies. Perhaps, the main reason why earlier viral-based therapies failed to achieve efficacy was due to a lack of full understanding of the viral biology. Now with 40 years of accumulated knowledge on viruses, promising viral vector-based strategies to treat genetic diseases are numerous. Some human diseases even have several effective treatment options to choose from. Typically, a viral vector is defined by three components as follows: (1) the protein capsid and/or envelope that encapsidates the genetic payload, and defines the vector’s tissue or cell tropism and antigen recognition; (2) the transgene of interest, which when expressed in cells, serves to confer a desired effect; and (3) the “regulatory cassette,” the combined enhancer/promoter/auxiliary elements that controls stable or transient somatic expression of the transgene as an episome or as a chromosomal integrant. Design aspects for these three components are different for each viral vector platform, have unique considerations, and harbor their own strengths and weaknesses. In this review, we will describe three viral vector platforms that have gained wide use for efficacious gene therapy and regulatory approval. These three strategies are based on Ads, AAVs, and lentiviruses (retroviruses), the viruses that a majority of gene therapy vectors are based upon (Fig. 2). For each of these vector platforms, we will review their general compositions and their mode of infection, highlight key vector platforms and their biological properties, describe current production strategies in use, feature their uses as commercialized drugs and in clinical trials, and finally discuss challenges and future outlooks.Fig. 2Summary of viral vectors used in clinical trials.a Pie chart showing the percentage of adenovirus, adeno-associated virus, or lentivirus vectors in use. b A table of the current number of clinical trials employing the different viral vectors. Data source: Wiley database on Gene Therapy Trials Worldwide. http://www.abedia.com/wiley/vectors.php Ad vectors: large cargo capacities for transient targeted gene delivery Structure and genome Ad is a non-enveloped virus that is known to mostly cause infections of the upper respiratory tract but can also infect other organs such as the brain and bladder. It possesses an icosahedral protein capsid that accommodates a 26- to 45-kb linear, double-stranded DNA genome. The Ad genome is flanked by hairpin-like inverted terminal repeats (ITRs) that vary in length (30–371 bp at its termini).5,6 The ITRs serve as self-priming structures that promote primase-independent DNA replication. A packaging signal located at the left arm of the genome is required for viral genome packaging. The Ad genome encodes ~35 proteins that are expressed in the early and late phases of viral gene transcription. The Ad genome comprises five so-called “early-phase” genes, E1A, E1B, E2, E3, and E4.7 The early-phase genes are transcribed before the initiation of viral DNA replication

Read the complete text